{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:45:42Z","timestamp":1780677942430,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068634"],"award-info":[{"award-number":["UM1 AI068634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068636"],"award-info":[{"award-number":["UM1 AI068636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI069481"],"award-info":[{"award-number":["UM1 AI069481"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI106701"],"award-info":[{"award-number":["UM1 AI106701"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Treatment management after repeated failure of antiretroviral therapy (ART) is difficult due to resistance and adherence challenges. For people who have failed non-nucleoside reverse transcriptase inhibitor-(NNRTI-) and protease inhibitor-(PI-) based regimens with no or limited resistance, remaining on PI-based ART is an option. Using data from an ART strategy trial (A5288) in low\/middle-income countries which included this option, we explored whether predictors can be identified distinguishing those who experienced further virologic failure from those who achieved and maintained virologic suppression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A5288 enrolled people with confirmed HIV-1 RNA\u2009\u2265\u20091000 copies\/mL after \u2265\u200924 weeks of PI-based ART and prior failure on NNRTI-based ART. This analysis focused on the 278 participants with no resistance to the PI being taken and no or limited nucleoside reverse transcriptase inhibitor (NRTI) resistance, who continued their PI with flexibility to change NRTIs. Proportional hazards models were used to evaluate predictors of virologic failure during follow-up (VF: confirmed HIV-1 RNA\u2009\u2265\u20091000 copies\/mL at \u2265\u200924 weeks of follow-up).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>56% of participants were female. At study entry, median age was 40 years, time on ART 7.8 years, CD4 count 169 cells\/mm<jats:sup>3<\/jats:sup>, HIV-1 RNA 20,444 copies\/mL; and 37% had NRTI resistance. The estimated proportion experiencing VF increased from 39% at week 24 to 60% at week 96. In multivariable analysis, significant predictors at study entry of VF were higher HIV-1 RNA (adjusted hazard ratio: 2.20 for \u2265\u200910,000 versus &lt;\u200910,000 copies\/mL), lower age (1.96 for &lt;\u200930 versus \u2265\u200930 years), NRTI resistance (1.74 for present versus absent), lower CD4 count (1.73 for &lt;\u2009200 versus \u2265\u2009200 cells\/mm<jats:sup>3<\/jats:sup>), and shorter ART duration (1.62 for &lt;\u200910 versus \u2265\u200910 years). There was a strong trend in proportion with VF at week 96 with the number of these five risk factors that a participant had, varying from 8% for zero, to 31%, 40%, 73%, and 100% for one, two, three, and four\/five. Only 13% of participants developed new NRTI or PI resistance mutations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A simple count of five predictors might have value for identifying risk of continued VF. Novel antiretroviral and adherence support interventions are needed to improve virologic outcomes for higher risk individuals.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-022-00494-9","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T07:07:05Z","timestamp":1672902425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance"],"prefix":"10.1186","volume":"20","author":[{"given":"Robert A.","family":"Salata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C.","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagalingeswaran","family":"Kumarasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Kanyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Mellors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole L.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ACTG A5288 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"issue":"10","key":"494_CR1","doi-asserted-by":"publisher","first-page":"e0164619","DOI":"10.1371\/journal.pone.0164619","volume":"11","author":"A Gupta","year":"2016","unstructured":"Gupta A, Junerja S, Vitoria M, et al. Projected uptake of new antiretroviral (ARV) medicines in adults in low- and middle-income countries; a forecast analysis 2015\u20132025. PLoS ONE. 2016;11(10):e0164619.","journal-title":"PLoS ONE"},{"key":"494_CR2","unstructured":"World Health Organization. Update of recommendations on first-and second-line antiretroviral regimens. Geneva, Switzerland: World Health Organization; 2019 (WHO\/CDS\/HIV\/19.15). Licence: CC BY-NC-SA 3.0 IGO.https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325892\/WHO-CDS-HIV-19.15-eng.pdf.\u00a0Accessed 11 Aug 2020."},{"issue":"Suppl 1","key":"494_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/QAD.0000000000000082","volume":"28","author":"V Cambiano","year":"2014","unstructured":"Cambiano V, Bertagnolio S, Jordan MR, et al. Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. AIDS. 2014;28(Suppl 1):15\u201323.","journal-title":"AIDS"},{"key":"494_CR4","doi-asserted-by":"publisher","first-page":"ciz1116","DOI":"10.1093\/cid\/ciz1116","volume":"14","author":"CL Wallis","year":"2019","unstructured":"Wallis CL, Hughes MD, Ritz J, et al. Diverse HIV-1 drug resistance profiles at screening for ACTG A5288: a study of people experiencing virologic failure on second-line ART in resource limited settings. Clin Infect Dis. 2019;14:ciz1116. https:\/\/doi.org\/10.1093\/cid\/ciz1116.","journal-title":"Clin Infect Dis"},{"key":"494_CR5","doi-asserted-by":"publisher","first-page":"24861","DOI":"10.3402\/gha.v7.24861","volume":"7","author":"S Khan","year":"2014","unstructured":"Khan S, Das M, Andries A, et al. Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India. Global Health Action. 2014;7:24861.","journal-title":"Global Health Action"},{"key":"494_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001883","author":"M Moorhouse","year":"2019","unstructured":"Moorhouse M, Maartens G, Venter WD, et al. Third-line antiretroviral therapy program in the south african public sector: cohort description and virological outcomes. J Acquir Immune Defic Syndr. 2019. https:\/\/doi.org\/10.1097\/QAI.0000000000001883.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"494_CR7","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S2352-3018(19)30146-8","volume":"6","author":"B Grinsztejn","year":"2019","unstructured":"Grinsztejn B, Hughes MD, Ritz J, et al. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Lancet HIV. 2019;6(9):e588\u2013600.","journal-title":"Lancet HIV"},{"key":"494_CR8","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/S2589-7500(19)30006-8","volume":"1","author":"R Gross","year":"2019","unstructured":"Gross R, Ritz J, Hughes MD, et al. Two-way mobile phone intervention compared to standard-of-care adherence support after second-line antiretroviral failure: a multinational, randomized controlled trial. Lancet Digit Health. 2019;1:e26\u201334.","journal-title":"Lancet Digit Health"},{"issue":"11","key":"494_CR9","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1086\/503914","volume":"42","author":"TF Liu","year":"2006","unstructured":"Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608\u201318.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"494_CR10","doi-asserted-by":"publisher","first-page":"e0220159","DOI":"10.1371\/journal.pone.0220159","volume":"14","author":"D Edessa","year":"2019","unstructured":"Edessa D, Sisay M, Asefa F. Second-line HIV treatment failure in sub-saharan Africa: a systematic review and meta-analysis. Plus One. 2019;14(7):e0220159.","journal-title":"Plus One"},{"issue":"3","key":"494_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3851\/IMP3005","volume":"21","author":"JD Ndahimana","year":"2016","unstructured":"Ndahimana JD, Riedel DJ, Mahayimpundu R, et al. HIV drug resistance mutations among patients failing second-line antitetroviral therapy in Rwanda. Antivir Ther. 2016;21(3):253\u20139.","journal-title":"Antivir Ther"},{"issue":"12","key":"494_CR12","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/jac\/dks310","volume":"67","author":"AI Maiga","year":"2012","unstructured":"Maiga AI, Fofana DB, Cisse M, et al. Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. J Antimicrob Chemother. 2012;67(12):2943\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"494_CR13","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/tmi.13131","volume":"23","author":"F Fily","year":"2018","unstructured":"Fily F, Ayikobua E, Ssemwanga D, et al. HIV-1 drug resistance testing at second-line regimen failure in Arua, Uganda: avoiding unnecessary switch to an empiric third-line. Trop Med Int Health. 2018;23(10):1075\u201383. doi:https:\/\/doi.org\/10.1111\/tmi.13131.","journal-title":"Trop Med Int Health"},{"issue":"2","key":"494_CR14","doi-asserted-by":"publisher","first-page":"ofy014","DOI":"10.1093\/ofid\/ofy014","volume":"5","author":"S Sawadogo","year":"2018","unstructured":"Sawadogo S, ShiningavamweA Roscoe C, et al. Human immunodeficiency virus-1 drug resistance patternsamong adult patients failing second-line protease inhibitor-containing regimensin Namibia, 2010\u20132015. Open Forum Infect Dis. 2018;5(2):ofy014. https:\/\/doi.org\/10.1093\/ofid\/ofy014.","journal-title":"Open Forum Infect Dis"},{"key":"494_CR15","volume-title":"HIV and adolescents: guidance for HIV testing and counselling and care for adolescents living with HIV: recommendations for a public health approach and considerations for policy-makers and managers","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. HIV and adolescents: guidance for HIV testing and counselling and care for adolescents living with HIV: recommendations for a public health approach and considerations for policy-makers and managers. Geneva: World Health Organization; 2013."},{"issue":"6","key":"494_CR16","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/09540121.2018.1554241","volume":"31","author":"CC Almeida-Brasil","year":"2019","unstructured":"Almeida-Brasil CC, Moodie EE, Cardoso TS, Nascimento ED, Ceccato MDGB. Comparison of the predictive performance of adherence measures for virologic failure detection in people living with HIV: a systematic review and pairwise meta-analysis. AIDS Care. 2019;31(6):647\u201359.","journal-title":"AIDS Care"},{"issue":"1","key":"494_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/QAI.0000000000002324","volume":"84","author":"C Godfrey","year":"2020","unstructured":"Godfrey C, Hughes MD, Ritz J, et al. Sex differences in outcomes for individuals presenting for third-line antiretroviral therapy. J Acquir Immune Defic Syndr. 2020;84(1):203\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"494_CR18","first-page":"141","volume":"20","author":"P Domingo","year":"2018","unstructured":"Domingo P, Mateo MG, Guiterrez MDM. Tolerability of current antiretroviral single-tablet regimens. AIDS Rev. 2018;20(3):141\u20139.","journal-title":"AIDS Rev"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-022-00494-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-022-00494-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-022-00494-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T22:03:32Z","timestamp":1673215412000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-022-00494-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["494"],"URL":"https:\/\/doi.org\/10.1186\/s12981-022-00494-9","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approvals were obtained from the institution review boards at all the participating clinical sites, as follows: Case Western Reserve University, Instituto Nacional de Infectologia Evandro Chagas, Harvard Longwood Campus (HLC) Institutional Review Board, University of Washington, Joint Clinical Research Centre, University of Pennsylvania Perelman School of Medicine, National Institutes of Health, YR Gaitonde Center for AIDS Research and Education, University of North Carolina, National Commission for Science and Technology Malawi, University of Pittsburgh, and the National Health Research Ethics Council (NHREC) (South Africa). Written informed consent was obtained from participants before undertaking study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}